MDT

82.53

-3.2%↓

A

122

+0.95%↑

VEEV

167.85

-0.65%↓

HQY

83.95

-2.51%↓

NEOG

9.42

-2.18%↓

MDT

82.53

-3.2%↓

A

122

+0.95%↑

VEEV

167.85

-0.65%↓

HQY

83.95

-2.51%↓

NEOG

9.42

-2.18%↓

MDT

82.53

-3.2%↓

A

122

+0.95%↑

VEEV

167.85

-0.65%↓

HQY

83.95

-2.51%↓

NEOG

9.42

-2.18%↓

MDT

82.53

-3.2%↓

A

122

+0.95%↑

VEEV

167.85

-0.65%↓

HQY

83.95

-2.51%↓

NEOG

9.42

-2.18%↓

MDT

82.53

-3.2%↓

A

122

+0.95%↑

VEEV

167.85

-0.65%↓

HQY

83.95

-2.51%↓

NEOG

9.42

-2.18%↓

Geron Corp

Затворен

СекторЗдравеопазване

1.5 -3.85

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.47

Максимум

1.56

Ключови измерители

By Trading Economics

Приходи

-10M

-29M

Продажби

788K

48M

Марж на печалбата

-60.11

Служители

258

EBITDA

-14M

-24M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+108.33% upside

Дивиденти

By Dow Jones

Следващи печалби

6.05.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-21M

1.1B

Предишно отваряне

5.35

Предишно затваряне

1.5

Настроения в новините

By Acuity

36%

64%

128 / 348 Класиране в Healthcare

Geron Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

20.04.2026 г., 23:49 ч. UTC

Значими събития в новините

New Zealand 1Q Inflation Higher Than Expected

20.04.2026 г., 23:10 ч. UTC

Горещи акции

Stocks to Watch: Amazon, Alaska Air Group, BridgeBio Oncology, AXT

20.04.2026 г., 22:53 ч. UTC

Значими двигатели на пазара

BridgeBio Oncology Shares Rise After FDA Fast-Tracks Pancreatic Cancer Treatment

20.04.2026 г., 23:45 ч. UTC

Пазарно говорене

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

20.04.2026 г., 23:44 ч. UTC

Пазарно говорене

Gold Consolidates as End of Cease-Fire Looms -- Market Talk

20.04.2026 г., 23:39 ч. UTC

Пазарно говорене

Rio Tinto Posts Strong Start to Year -- Market Talk

20.04.2026 г., 23:30 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

20.04.2026 г., 23:30 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

20.04.2026 г., 23:30 ч. UTC

Пазарно говорене

Super Retail's Earnings Outlook Less Rosy -- Market Talk

20.04.2026 г., 23:09 ч. UTC

Пазарно говорене

Viva Energy's Refinery Fire More Benign Than Jefferies Thought -- Market Talk

20.04.2026 г., 22:31 ч. UTC

Придобивния, сливания и поглъщания

Anthropic, Amazon Tighten Bond in $5 Billion Investment and Computing Deal -- WSJ

20.04.2026 г., 22:26 ч. UTC

Придобивния, сливания и поглъщания

West African Resources Says Sanbrado, Toega Operations Not Subject to Govt Request for Additional Participation

20.04.2026 г., 22:25 ч. UTC

Придобивния, сливания и поглъщания

West African Resources Plans to Distribute Cash Proceeds to Shareholders Via Special Dividend

20.04.2026 г., 22:25 ч. UTC

Придобивния, сливания и поглъщания

West African Resources Aims for Acquisition to Be Completed by End-2026

20.04.2026 г., 22:25 ч. UTC

Придобивния, сливания и поглъщания

West African Resources Says to Work Cooperatively With Govt to Finalize Deal Terms

20.04.2026 г., 22:25 ч. UTC

Придобивния, сливания и поглъщания

West African Resources Says Acquisition Would Be for A$175 Million

20.04.2026 г., 22:24 ч. UTC

Придобивния, сливания и поглъщания

West African Resources Says Burkina Faso Govt Issues Decree to Acquire 25% of Kiaka

20.04.2026 г., 22:15 ч. UTC

Придобивния, сливания и поглъщания

Anthropic, Amazon Tighten Bond in $5 Billion Investment and Computing Deal -- WSJ

20.04.2026 г., 22:01 ч. UTC

Придобивния, сливания и поглъщания

Amazon Invests $5B in Anthropic Amid Expanded Collaboration

20.04.2026 г., 21:38 ч. UTC

Пазарно говорене

Apple's New CEO Will Face Immediate Pressure on AI Strategy -- Market Talk

20.04.2026 г., 21:33 ч. UTC

Придобивния, сливания и поглъщания

Uber Expands Stake In Lucid for Robo-Taxis. This Is How Tesla's Stock Is Responding. -- Barrons.com

20.04.2026 г., 21:24 ч. UTC

Пазарно говорене

Apple's CEO Change Timing Will Garner Mixed Reaction, Analyst Says -- Market Talk

20.04.2026 г., 21:24 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

20.04.2026 г., 21:13 ч. UTC

Печалби

Alaska Air: Expansion of Card Portfolio Expected to Accelerate Loyalty Platform Beyond Incremental $150M Profit Outlined in Alaska Accelerate Strategy

20.04.2026 г., 21:10 ч. UTC

Печалби

Alaska Air to Move Toward a Single Issuer for Atmos Rewards Credit Cards

20.04.2026 г., 21:09 ч. UTC

Печалби

Alaska Air Sees 2Q Capacity Up About 1% Year-Over-Year, Down Nearly a Point From Original Views, on 'Proactive Trimming' of May and June Capacity

20.04.2026 г., 21:08 ч. UTC

Печалби

Alaska Air 'Continues to Operate From a Position of Strength,' With Healthy Balance Sheet, Strong Liquidity, About $20B in Unencumbered Assets

20.04.2026 г., 21:07 ч. UTC

Печалби

Alaska Air: Taken Together, Rev, Cost and Fuel Assumptions Result in 2Q Adjusted Loss Per Share Estimate of About $1

20.04.2026 г., 21:05 ч. UTC

Печалби

Alaska Air: This Assumption Adds About $600M of Expense to 2Q, Equivalent to EPS Headwind of $3.60

20.04.2026 г., 21:05 ч. UTC

Печалби

Alaska Air Expects 2Q Fuel Cost to Average About $4.50 Based on Forward Curve Today

Сравнение с други в отрасъла

Ценова промяна

Geron Corp Прогноза

Ценова цел

By TipRanks

108.33% нагоре

12-месечна прогноза

Среден 3.25 USD  108.33%

Висок 5 USD

Нисък 1 USD

Според 5 анализатори от Wall Street, предложили 12-месечна ценова цел за Geron Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

5 ratings

3

Купи

1

Задържане

1

Продай

Настроение

By Acuity

128 / 348 Класиране в Здравеопазване

Настроения в новините

Бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Geron Corp

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
help-icon Live chat